AstraZeneca kicks off Phase 1 trial of potential COVID-19 therapy

AstraZeneca has dosed the first participants in a Phase I trial (48 healthy participants in UK aged 18 to 55 years) of AZD7442, a combination of two monoclonal antibodies being developed for prevention and treatment of COVID-19.

Source:

PharmaTimes